Compare CRDL & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | BTMD |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 90.6M |
| IPO Year | N/A | N/A |
| Metric | CRDL | BTMD |
|---|---|---|
| Price | $1.09 | $2.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $9.00 | $6.00 |
| AVG Volume (30 Days) | ★ 693.6K | 130.4K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.48 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $195,645,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.80 |
| P/E Ratio | ★ N/A | $3.68 |
| Revenue Growth | N/A | ★ 1.34 |
| 52 Week Low | $0.77 | $2.32 |
| 52 Week High | $1.59 | $6.78 |
| Indicator | CRDL | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 59.27 |
| Support Level | $0.88 | $2.32 |
| Resistance Level | $1.12 | $2.61 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 85.42 | 88.46 |
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.